Financial Data and Key Metrics Changes - For Q3 2025, net income per share was $0.03 and core FFO per share grew to $0.76, slightly above expectations [16] - Cash available for distribution was $29.3 million, reflecting steady operational performance [16] - Core FFO growth from 2024 to the midpoint of guidance for 2025 was reported at 3% [10] Business Line Data and Key Metrics Changes - The portfolio occupancy remained near historical highs at 97% with a weighted average lease term of approximately ten years [10] - The recent acquisition of York Space Systems headquarters in Colorado aligns with the goal of 15% government-adjacent exposure [11] Market Data and Key Metrics Changes - The company continues to maintain strong relationships across agencies and has refined its balance sheet with a disciplined approach to capital deployment [10] - The development pipeline remains active, with major projects progressing, including the FDA Atlanta project nearing completion [18] Company Strategy and Development Direction - The company is focused on three long-term priorities: growing core FFO by 2% to 3% annually, increasing same-store performance through diversification, and executing value-creating development opportunities [7] - The strategy aims to balance growth and durability, ensuring consistent performance regardless of economic or policy changes [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the government will not default on leases, viewing shutdowns as part of budget negotiations [5] - The company is optimistic about its growth strategy and the opportunities ahead, emphasizing the importance of mission-critical facilities [14] Other Important Information - The company is targeting a medium-term cash leverage goal of six times, down from historical levels of seven to eight times [13] - The acquisition team has built a robust pipeline, allowing for selective capital deployment [12] Q&A Session Summary Question: Update on Flagstaff warehouse completion - The completion has been pushed out two quarters due to ongoing design work by the government, but the new date is considered achievable [24] Question: Thoughts on capital allocation and funding sources - The company is focused on cost of equity and believes it can develop at a spread above its cost of capital, with strong relationships with sovereign wealth funds [25][27] Question: Acquisition guidance for 2026 - The $50 million acquisition guidance is set low to manage expectations, with a strong pipeline of $1.5 billion identified [31][34] Question: Impact of government shutdown on leasing - The shutdown slows processes but does not diminish portfolio value, with agencies continuing to work effectively [40][42] Question: Achieving six times cash flow leverage - The company plans to leverage attractive development projects and joint ventures to reach its leverage target [46][50] Question: Changes in growth strategy - The focus has shifted to lower leverage with moderate growth to improve cost of capital, while still aiming for 2% to 3% growth [69][76] Question: 2026 guidance and headwinds - The guidance reflects growth from FDA Atlanta and same-store growth, offset by increased G&A expenses [81][84] Question: Government shutdown and lease funding - All leases are funded for six months, and the company expects the government to meet its obligations despite shutdowns [86][88]

Financial Data and Key Metrics Changes - For Q3 2025, net income per share was $0.03, and core FFO per share grew to $0.76, slightly above expectations [11] - Cash available for distribution was $29.3 million, reflecting steady operational performance [11] - Core FFO growth from 2024 to the midpoint of guidance for 2025 was 3%, driven by acquisitions and strong renewal execution [7][11] Business Line Data and Key Metrics Changes - The company maintained high portfolio occupancy at 97% and a weighted average lease term of approximately 10 years, indicating strong tenancy durability [7] - Recent acquisition of York Space Systems headquarters in Colorado aligns with the goal of 15% government-adjacent exposure [8] Market Data and Key Metrics Changes - The company is focused on diversifying its portfolio with state and local government leases, which can extend lease terms up to 40 years, enhancing weighted average lease term [12] - The development pipeline remains active, with major projects like the FDA Atlanta nearing completion, expected to drive future earnings growth [12][67] Company Strategy and Development Direction - The company’s growth strategy is centered on three long-term priorities: growing core FFO by 2-3% annually, increasing same-store performance through diversification, and executing value-creating development opportunities [5] - The company aims to improve its cost of capital through leverage optimization, targeting a medium-term cash leverage goal of six times, down from historical levels of seven to eight times [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the government will not default on leases despite the ongoing federal government shutdown, viewing it as a negotiating tool rather than a threat [4][73] - The company remains optimistic about its growth trajectory, with a focus on delivering essential real estate that supports government operations [10][77] Other Important Information - The company has successfully extended leases at key properties, including USCIS Lincoln and VA Golden, and continues to find the government a constructive partner [11] - The company’s guidance for full-year core FFO per share for 2025 is narrowed to a range of $2.98 to $3.02, consistent with its growth objectives [14] Q&A Session Summary Question: What is the status of the Flagstaff Courthouse completion? - The completion date has been pushed out two quarters due to ongoing design work involving multiple agencies, but the new date is considered achievable [18] Question: Can you discuss your thoughts on capital allocation and funding sources for development? - The company is exploring various funding sources, including partnerships with sovereign wealth funds, to optimize capital allocation while managing costs [19][22] Question: What is the reasoning behind the $50 million acquisition guidance for 2026? - The guidance reflects a conservative approach amid cost of capital challenges, but the company expects to identify opportunities within its $1.5 billion pipeline [25][27] Question: Will dispositions be part of achieving your leverage target? - Dispositions may be considered, but the company believes it can achieve its leverage goals through acquisitions and partnerships without needing to sell assets [28][29] Question: How does the government shutdown affect leasing and agency operations? - While the shutdown may slow processes, it does not threaten the value of the portfolio, and the company expects a quick catch-up once operations resume [30][31] Question: Can you elaborate on the strategy for achieving six times cash flow leverage? - The company plans to leverage development projects effectively while maintaining a focus on growth, aiming for a gradual reduction in leverage over the next few years [33][36] Question: What are the expectations for 2026 guidance and potential headwinds? - The 2026 guidance reflects growth primarily from the FDA Atlanta project, with expectations for same-store growth offset by increased G&A expenses [67][70]